SciClone Pharmaceuticals to Present at Two Investor Conferences in March

FOSTER CITY, CA, Mar 01 (MARKET WIRE) --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it
will present at two upcoming investor conferences: Cowen Healthcare
Conference and Rodman & Renshaw Annual China Investment Conference.
SciClone's executives will present a corporate overview and business
update at each conference.

WHEN:
Cowen Healthcare Conference
Monday,
March 7 at 1:00 pm ET
Boston, MA
Presenter: Gary Titus, Senior Vice
President and CFO

WHEN:
Rodman & Renshaw Annual China Investment
Conference
Tuesday, March 8 at 2:00 pm Shanghai time
Shanghai, China

Presenter: Friedhelm Blobel, Ph.D., President and CEO

To access the live audio webcasts of the Rodman & Renshaw presentation,
please log on through a link located in the Investor Relations section of
SciClone's website at www.sciclone.com. At the Cowen conference, SciClone
is presenting on a panel that is not being webcast by the conference
organizers.

About SciClone
SciClone Pharmaceuticals (NASDAQ: SCLN) is a
revenue-generating, China-centric, specialty pharmaceutical company with
a substantial international business and a product portfolio of novel
therapies for cancer and infectious diseases. The Company is focused on
continuing sales growth and executing a clinical development strategy
with prudently managed costs. ZADAXIN(R) (thymalfasin) is approved in
over 30 countries for the treatment of hepatitis B (HBV), as a vaccine
adjuvant, for the treatment of hepatitis C (HCV), and certain cancers.
SciClone is evaluating SCV-07 in a phase 2b trial to modify the course of
oral mucositis in patients with head and neck cancer. The Company also
has exclusive commercialization and distribution rights in China to a
novel treatment for advanced liver cancer, DC Bead(R), which is already
approved in approximately 40 countries worldwide, including the U.S. and
several countries in Europe. DC Bead is currently under review by
regulatory agencies in China. Additionally, SciClone owns exclusive
commercialization and distribution rights to the anti-nausea drug
ondansetron RapidFilm(R) in China, including Hong Kong and Macau, and
Vietnam. The Company intends to seek regulatory approval for the product,
commonly used to treat and prevent nausea and vomiting caused by
chemotherapy, radiotherapy, and surgery, in these markets. For additional
information, please visit www.sciclone.com.

DC Bead is a registered trademark of Biocompatibles UK Limited.

RapidFilm is a registered trademark of Labtec Gesellschaft fuer
technologische Forschung und Entwicklung mbH.

Contact
Ana Kapor
Investors/Media
650.350.4825
investorrelations@sciclone.com

Copyright 2011, Market Wire, All rights reserved.

-0-